Seronegative antibody-mediated neurology after immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Seronegative antibody-mediated neurology after immune checkpoint inhibitors

Published:2018-03-25 Issue:5 Volume:5 Page:640-645
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Wilson Robert¹,Menassa David A.¹,Davies Alexander J.¹,Michael Sophia¹,Hester Joanna²,Kuker Wilhelm³,Collins Graham P.⁴,Cossins Judith¹,Beeson David¹,Steven Neil⁵,Maddison Paul⁶,Rinaldi Simon¹,Jacob Saiju⁷,Irani Sarosh R.¹^ORCID

Affiliation:

1. Oxford Autoimmune Neurology Group; Nuffield Department of Clinical Neurosciences; University of Oxford; John Radcliffe Hospital; Oxford United Kingdom

2. Nuffield Department of Surgical Sciences; University of Oxford; John Radcliffe Hospital; Oxford United Kingdom

3. Neuroradiology Department; Oxford University Hospitals; Oxford United Kingdom

4. Department of Clinical Haematology; Churchill Hospital; Oxford United Kingdom

5. Department of Clinical Oncology; University Hospitals Birmingham; Birmingham United Kingdom

6. Department of Neurology; Queen's Medical Centre; Nottingham United Kingdom

7. Centre for Rare Diseases and Queen Elizabeth Neuroscience Centre; University Hospitals Birmingham; Birmingham United Kingdom

Funder

British Medical Association

Epilepsy Research UK

Wellcome Trust

Fulbright UK-US commission

Medical Research Council

KRUK

National Institute for Health Research

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Reference19 articles.

1. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?;Tanvetyanon;Expert Opin Biol Ther,2017

2. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives;Yshii;Nat Rev Neurol,2017

3. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4 + CD25Hi regulatory T cells;Wang;Int Immunol,2009

4. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study;Antonia;Lancet Oncol,2016

5. Neurological immune-related adverse events of ipilimumab;Bot;Pract Neurol,2013

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes;The Lancet Neurology;2024-01

2. Role of B cells in immune‐related adverse events following checkpoint blockade;Immunological Reviews;2023-07-08

3. Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors;Frontiers in Neuroscience;2023-06-29

4. Neurologic Complications of Cancer Immunotherapy;Current Oncology;2023-06-19

5. A case of Guillain-Barré Syndrome after atezolizumab and bevacizumab combination therapy for multiple lung metastases from hepatocellular carcinoma;Kanzo;2023-05-01